Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …

Background: Exon 19 deletion and L858R point mutation of the epidermal growth factor
receptor (EGFR) are the most commonly encountered EGFR mutations in non-small cell …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Context: Epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) are
considered to be effective treatments for advanced NSCLC patients with sensitizing EGFR …

Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …

19072 Background: Non-small cell lung cancer (NSCLC) patients with epidermal growth
factor receptor (EGFR) mutation show excellent response to gefitinib, but eventually develop …

Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …